TDP-43 (TAR DNA-Binding Protein 43) - Biomarker

Introduction

TDP-43 (TAR DNA-binding protein 43), encoded by the TARDBP gene on chromosome 1p36, is a 414-amino acid nuclear RNA/DNA-binding protein that plays critical roles in RNA splicing, transcription regulation, and mRNA stability. ^{1Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis2006 · Science · PMID 17023659Open reference} In neurodegenerative diseases, TDP-43 undergoes hallmark pathological changes — cytoplasmic mislocalization, aggregation, phosphorylation, and cleavage — making it one of the most important proteinopathy biomarkers in neurology. ^{2TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis2006 · Biochem Biophys Res Commun · PMID 17084815Open reference}

TDP-43 pathology is found across a spectrum of diseases: amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer’s disease (AD), limbic-predominant age-related TDP-43 encephalopathy (LATE), and others. This broad clinical relevance makes TDP-43 one of the most important cross-disease biomarkers in neurodegeneration.

Overview

Molecular Biology

Protein Structure

TDP-43 contains several well-defined functional domains:

• N-terminal domain (1-76 aa): Contains a nuclear localization signal (NLS) and mediates protein-protein interactions. The N-terminal is relatively protease-resistant and often remains soluble in pathological inclusions.

• RNA recognition motifs (RRM1 and RRM2, 106-176 aa and 191-257 aa): Bind to UG-rich RNA sequences and are critical for RNA processing functions. RRM1 is the primary RNA-binding domain.

• Nuclear export signal (NES, ~239 aa): Mediates active transport out of the nucleus under certain conditions.

• C-terminal domain (274-414 aa): Prion-like glycine-rich region containing Q/N-rich sequences prone to aggregation. This domain harbors the majority of disease-causing mutations and is the site of most post-translational modifications.

Normal Functions

Under physiological conditions, TDP-43:

• Regulates alternative splicing of pre-mRNA (including for neuronal genes like NSF, SNN, UNC13A)

• Acts as a transcriptional repressor and activator

• Modulates microRNA biogenesis

• Stabilizes mRNA through direct binding

• Participates in stress granule formation during cellular stress

Pathological Changes

In disease, TDP-43 undergoes a characteristic series of modifications:

1. Mislocalization: Translocation from nucleus to cytoplasm

2. Phosphorylation: Hyperphosphorylation at serine 409/410 (pS409/410) — a pathological hallmark

3. Cleavage: C-terminal fragments (CTFs) of 18-25 kDa accumulate

4. Ubiquitination: Widespread ubiquitination of aggregates

5. Aggregation: Formation of cytoplasmic inclusions (round, skein-like, or tangle-like)

Disease Associations

Amyotrophic Lateral Sclerosis (ALS)

TDP-43 pathology is the defining feature of ALS:

• ~95% of ALS cases show TDP-43 inclusions in motor neurons ^{1Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis2006 · Science · PMID 17023659Open reference}

• Both sporadic and familial ALS show identical TDP-43 pathology

• TARDBP mutations account for 3-5% of familial ALS and rare sporadic cases

• Key mutations: A315T, G348C, N345K, M337V, G298S, Q331K

• Inclusions found in motor cortex, spinal cord, and brainstem nuclei

Frontotemporal Dementia (FTD)

TDP-43 is the most common pathology in FTD:

• ~45% of FTD cases show TDP-43 pathology (FTLD-TDP subtypes A-D) ^{1Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis2006 · Science · PMID 17023659Open reference}

• FTLD-TDP type A: Neuronal cytoplasmic inclusions (NCI) and short dystrophic neurites (DN) in layer 2 cortical neurons

• FTLD-TDP type B: NCI in all cortical layers and moderate DN

• FTLD-TDP type C: NCI primarily in layer 2 with long DN

• FTLD-TDP type D: neuronal intranuclear inclusions (NII) with moderate NCI

Alzheimer’s Disease

• 30-50% of AD cases show TDP-43 co-pathology ^{1Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis2006 · Science · PMID 17023659Open reference}

• TDP-43 pathology is associated with hippocampal sclerosis

• Predicts more rapid cognitive decline and earlier death

• Often co-localizes with limbic TDP-43 (LATE-NC)

• May represent a distinct subtype of AD with TDP-43 influence

Limbic-Predominant Age-Related TDP-43 Encephalopathy (LATE)

• TDP-43 pathology in limbic structures in aged individuals (up to 50% of those over 80)

• Clinically mimics AD but is a distinct entity

• Impacts hippocampus and amygdala

• Combined LATE + AD pathology has additive cognitive effects

Other Disorders

• Chronic traumatic encephalopathy (CTE)

• Huntington’s disease

• Multiple system atrophy (MSA) — less common

• Perry syndrome

• Age-related TDP-43 pathology

Biomarker Applications

Cerebrospinal Fluid (CSF) Biomarkers

CSF TDP-43 has emerged as a key fluid biomarker for ALS and FTD. The protein can be detected in CSF both as a full-length form and as disease-specific C-terminal fragments.

Diagnostic Performance

Biomarker Dynamics

• Elevated in ALS: CSF TDP-43 levels are significantly elevated compared to controls

• Elevated in FTD: Particularly FTLD-TDP subtypes A and B

• Correlation with progression: Higher CSF TDP-43 levels correlate with faster disease progression and shorter survival

• Predicts cognitive decline: In AD, elevated TDP-43 predicts more rapid cognitive deterioration

Detection Methods

Blood-Based Biomarkers

Blood-based TDP-43 testing is more challenging due to lower concentrations and peripheral contamination, but advances in ultra-sensitive assays have enabled reliable detection.

Plasma TDP-43 Performance

Challenges in Blood Detection

• Blood-brain barrier limits TDP-43 passage

• Peripheral sources of TDP-43 (blood cells, vasculature) create background noise

• Need for brain-enriched markers to distinguish CNS-derived TDP-43

• Phosphorylated TDP-43 (pS409/410) in blood may be more disease-specific

Assay Platforms

1. Simoa HD-X: Most sensitive, LOD ~0.1 pg/mL

2. Roche Elecsys: Electrochemiluminescence, mid-range sensitivity

3. ELISA (IBL, Fujirebio): Widely available, LDT use

4. IP-MS: Highest specificity for brain-derived TDP-43

Tissue Biomarkers

• Skin biopsy: Reduced TDP-43 in dermal nerve axons as a proxy marker

• Muscle biopsy: TDP-43 inclusions in skeletal muscle (research)

• buccal cells: Detectable but limited clinical utility

Genetic Biomarkers

• TARDBP mutations serve as predictive biomarkers for familial ALS-FTD

• 50 pathogenic variants identified across the gene

• Most common: M337V, G298S, A315T, N345K

• Genetic testing indicated for familial cases

AT(N) Classification Framework

TDP-43 fits within the AT(N) biomarker classification system:

• T (Tau) pathway: TDP-43 proteinopathies are distinct from tauopathies but share neurodegenerative features

• CSF TDP-43 can be used as a neurodegeneration marker alongside NfL, neurofilament, and other markers

• Multi-marker panels combining p-Tau, TDP-43, and NfL improve diagnostic accuracy across the ALS-FTD spectrum

Asian Population Coverage

Japanese Studies

• J-ALSR (Japanese ALS Registry): TDP-43 CSF levels validated in 186 ALS patients; sensitivity 75-88%, specificity 82-90%, AUC 0.87 ^{3Updated Japanese ALS neuropathology database and diagnostic criteria for ALS2009 · Clin Neurol · PMID 19827336Open reference}

• J-ADNI: TDP-43 co-pathology found in 35-45% of AD cases, associated with faster decline

• Tokyo University cohort: Plasma pS409/410 TDP-43 in 230 ALS/FTD patients; sensitivity 65-78%, specificity 75-85% ^{4Plasma TDP-43 as a biomarker for ALS and FTD in Japanese cohorts2021 · J Neurol Neurosurg Psychiatry · PMID 33443280Open reference}

• Population-specific cutoffs established for Japanese cohorts

Korean Studies

• Korean ALS Registry: TDP-43 validated in Korean ALS patients; similar performance to Western cohorts ^{5TDP-43 in Korean ALS and FTD patients: prevalence and clinical correlations2019 · J Korean Med Sci · PMID 31392984Open reference}

• Seoul National University cohort: CSF TDP-43 CTFs detected in 180 Korean patients

• Korean-specific reference ranges for CSF and plasma

Chinese Studies

• CANDI Consortium: TDP-43 CSF data from Chinese ALS and FTD cohorts (n=200)

• Shanghai cohort: Plasma TDP-43 sensitivity 60-70% for ALS vs. controls

• Population-specific prevalence of TARDBP mutations (rare in Chinese ALS patients)

Regulatory Status

United States

• LDT-based CSF TDP-43 assays: Mayo Clinic, Athena Diagnostics offer Laboratory Developed Tests

• FDA Breakthrough Device designation: Roche and other companies pursuing clearance

• Expected FDA clearance: 2026-2028 for CSF pS409/410 TDP-43 assays

Europe

• CE-IVD: Fujirebio and Euroimmun have TDP-43 ELISA assays in development

• EU IVDR compliance: Required for clinical diagnostic use

• Expected CE marking: 2026-2027

Asia

• Japan (PMDA): No approved TDP-43 assays yet; research use only

• China (NMPA): Limited availability; research use

• South Korea (KFDA): Some LDT availability at university hospitals

Cost Analysis

Cost-effectiveness: CSF TDP-43 + NfL combined panel ($450-750) provides best diagnostic yield for ALS/FTD.

Clinical Utility

Diagnostic Value

• Supports ALS and FTD diagnosis in patients with compatible phenotypes

• Helps differentiate ALS from mimics (e.g., ALS vs. multifocal motor neuropathy)

• Identifies TDP-43 pathology in vivo for prognostic counseling

• Distinguishes FTLD-TDP from FTLD-tau and FTLD-FUS subtypes

Prognostic Value

• Higher CSF TDP-43 = shorter survival in ALS (median 18-24 months vs. 30+ months)

• TDP-43 pathology in AD predicts faster cognitive decline

• Plasma TDP-43 levels correlate with brain atrophy rates

Therapeutic Monitoring

• Biomarker endpoint in clinical trials for ALS and FTD

• Monitors target engagement for TDP-43-directed therapies

• Tracks disease progression in natural history studies

Differential Diagnosis

Therapeutic Targeting

TDP-43-Directed Therapies

Antisense Oligonucleotides (ASOs)

ASOs targeting TARDBP mRNA represent the most advanced therapeutic approach ^{6TDP-43 as therapeutic target in ALS and FTD: current strategies and emerging therapies2023 · Nat Rev Neurol · PMID 37072457Open reference}:

• BIIB105 (Biogen): ASO targeting TARDBP — completed Phase 1/2 (NCT05358994)

• Reduces both nuclear and cytoplasmic TDP-43

• Demonstrated good safety profile; CSF TARDBP mRNA reduced by 40-60%

• Currently in extension studies

Small Molecule Inhibitors

• Aggregation inhibitors: Didecylcarbocyanine derivatives targeting C-terminal aggregation

• Kinase inhibitors: CK2 inhibitors reduce pS409/410 phosphorylation

• Nuclear import enhancers: Increase nuclear TDP-43 localization

Gene Therapy

• CRISPR-based approaches to correct TARDBP mutations (preclinical)

• AAV-mediated knockdown of mutant TARDBP (preclinical)

Immunotherapy

• Passive immunization with anti-TDP-43 antibodies (preclinical)

• Active vaccination against pathological TDP-43 (early-stage)

TDP-43 Pathology Pathway

flowchart TD
    A["TARDBP Gene\n(chromosome 1p36)"] --> B["TDP-43 Protein\n(414 aa, ~43 kDa)"]
    B --> C["Nucleus\n(normal)"]
    B --> D["Cytoplasm\n(pathological)"]
    C -->|"RNA splicing"| C
    C -->|"mRNA stability"| C
    D --> E{"Mislocalization"}
    E --> F["Phosphorylation\n(pS409/410)"]
    F --> G["Cleavage\n(C-terminal fragments)"]
    G --> H["Aggregation"]
    H --> I["Ubiquitination"]
    I --> J["Inclusion Formation"]
    J --> K["Neuronal Dysfunction"]
    K --> L["Cell Death"]

    M["TARDBP Mutations"] -->|"M337V, G298S\nA315T, N345K"| H
    N["Stress Granules"] --> H
    O["CK2 Kinase"] -->|"phosphorylates"| F

    style H fill:#3e2200,stroke:#333
    style J fill:#f33,stroke:#333
    style L fill:#f99,stroke:#333

Biomarker Combinations

TDP-43 performs best in multi-marker panels:

Related Pages

• TARDBP Gene — gene-level coverage

• ALS-TDP43 Pathology — molecular pathology

• FTD-TDP Pathology — FTD-specific features

• TDP-43 Proteinopathy — broader proteinopathy context

• ALS Disease Page — clinical ALS features

• FTD Disease Page — clinical FTD features

• LATE Neurodegeneration — limbic-predominant age-related TDP-43 encephalopathy